



FEP Medical Policy Manual

FEP 2.02.30 Transcatheter Mitral Valve Repair

Effective Policy Date: October 1, 2021

Original Policy Date: December 2015

Related Policies:

7.01.132 - Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Transcatheter Mitral Valve Repair

Description

Transcatheter mitral valve repair (TMVR) is an alternative to surgical therapy for mitral regurgitation (MR). MR is a common valvular heart disease that can result from a primary structural abnormality of the mitral valve (MV) complex or a secondary dilatation of an anatomically normal MV due to a dilated left ventricle caused by ischemic or dilated cardiomyopathy. Surgical therapy may be underutilized, particularly in patients with multiple comorbidities, suggesting that there is an unmet need for less invasive procedures for MV repair. One device, MitraClip, has approval from the U.S. Food and Drug Administration for the treatment of severe symptomatic MR due to a primary abnormality of the MV (primary MR) in patients considered at prohibitive risk for surgery and for patients with heart failure and moderate-to-severe or severe symptomatic secondary MR despite the use of maximally tolerated guideline-directed medical therapy.

Mitral Regurgitation (MR) is the second most common valvular heart disease, occurring in 7% of people older than age 75 years and accounting for 24% of all patients with valvular heart disease.^{1,2} MR with accompanying valvular incompetence leads to left ventricular (LV) volume overload with secondary ventricular remodeling, myocardial dysfunction, and left heart failure. Clinical signs and symptoms of dyspnea and orthopnea may also be present in patients with valvular dysfunction.³ MR severity is classified as mild, moderate, or severe disease on the basis of echocardiographic and/or angiographic findings (1+, 2+, and 3-4+ angiographic grade, respectively).

Patients with MR generally fall into 2 categories: primary (also called degenerative) and secondary (also called functional) MR. Primary MR results from a primary structural abnormality in the valve, which causes it to leak. This leak may result from a floppy leaflet (called prolapse) or a ruptured cord that caused the leaflet to detach partially (called flail).⁴ Because the primary cause is a structural abnormality, most cases of primary MR are surgically corrected. Secondary MR results from LV dilatation due to ischemic or dilated cardiomyopathy. This causes the mitral valve (MV) leaflets not to coapt

or meet in the center.³ Because the valves are structurally normal in secondary MR, correcting the dilated LV using medical therapy is the primary treatment strategy used in the U. S.

OBJECTIVE

The objective of this evidence review is to determine whether transcatheter mitral valve repair improves the net health outcome in patients with primary (degenerative) or secondary (functional) mitral regurgitation.

POLICY STATEMENT

Transcatheter mitral valve repair (TMVR) with a device approved by the U.S. Food and Drug Administration (FDA) for use in mitral valve repair may be considered **medically necessary** for patients with symptomatic, primary mitral regurgitation (MR) who are considered at prohibitive risk for open surgery (see Policy Guidelines section).

TMVR with a device approved by the U.S. FDA may be considered **medically necessary** for patients with heart failure and moderate-to-severe or severe symptomatic secondary MR despite the use of maximally tolerated guideline-directed medical therapy (see Policy Guidelines section).

TMVR is considered **investigational** in all other situations.

POLICY GUIDELINES

"Prohibitive risk" for open surgery may be determined based on:

- Presence of a Society for Thoracic Surgeons predicted mortality risk of 12% or greater and/or
- Presence of a logistic EuroSCORE of 20% or greater.

Moderate to severe or severe MR may be determined by:

- Grade 3+ (moderate) or 4+ (severe) MR confirmed by echocardiography
- New York Heart Association (NYHA) functional class II, III, or IVa (ambulatory) despite the use of stable maximal doses of guideline-directed medical therapy and cardiac resynchronization therapy (if appropriate) administered in accordance with guidelines of professional societies.

Optimal medical therapy may be determined by guidelines from specialty societies (e.g., American Heart Association/American College of Cardiology Guideline for the Management of Patients with Valvular Heart Disease, European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines for the Management of Valvular Heart Disease, American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure (refer to supplemental materials for guideline citations)).

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Surgical Management

In symptomatic patients with primary MR, surgery is the main therapy. In most cases, MV repair is preferred over replacement, as long as the valve is suitable for repair and personnel with appropriate surgical expertise are available. The American College of Cardiology and the American Heart Association have issued joint guidelines on the surgical management of MV (See Supplemental Information).⁵

The use of standard open MV repair is limited by the requirement for thoracotomy and cardiopulmonary bypass, which may not be tolerated by elderly or debilitated patients due to their underlying cardiac disease or other conditions. In a single-center evaluation of 5737 patients with severe MR in the U.S., Goel et al (2014) found that 53% of patients did not have MV surgery performed, suggesting an unmet need for such patients.⁶

Isolated MV surgery (repair or replacement) for severe chronic secondary MR is not generally recommended because there is no proven mortality reduction and an uncertain durable effect on symptoms. Recommendations from major societies^{7,8} regarding MV surgery in conjunction with coronary artery bypass graft surgery or surgical aortic valve replacement are weak because the current evidence is inconsistent on whether MV surgery produces a clinical benefit.^{9,10,11,12}

Transcatheter Mitral Valve Repair

Transcatheter approaches have been investigated to address the unmet need for less invasive MV repair, particularly among inoperable patients who face prohibitively high surgical risks due to age or comorbidities. MV repair devices under development address various components of the MV complex and generally are performed on the beating heart without the need for cardiopulmonary bypass.^{1,13} Approaches to MV repair include direct leaflet repair,¹⁴ repair of the mitral annulus via direct annuloplasty, or indirect repair based on the annulus's proximity to the coronary sinus. There are also devices in development to counteract ventricular remodeling, and systems designed for complete MV replacement via catheter.

Direct Leaflet Approximation

One device that undertakes direct leaflet repair, the MitraClip Clip Delivery System (Abbott Vascular), has been approved through the premarket approval process by the U.S. Food and Drug Administration (FDA) for use in certain patients with symptomatic primary MR (see Regulatory Status section). Of the transcatheter MV repair devices under investigation, MitraClip has the largest body of evidence evaluating its use; it has been in use in Europe since 2008.¹⁴ The MitraClip system is deployed percutaneously and approximates the open Alfieri edge-to-edge repair approach to treating MR. The delivery system consists of a catheter, a steerable sleeve, and the MitraClip device, which is a 4-mm wide clip fabricated from a cobalt-chromium alloy and polypropylene fabric. MitraClip is deployed via a transfemoral approach, with transseptal puncture used to access the left side of the heart and the MV. Placement of MitraClip leads to coapting of the mitral leaflets, thus creating a double-orifice valve.

Other Mitral Valve Repair Devices

Devices for TMVR that use different approaches are in development. Techniques to repair the mitral annulus include those that target the annulus itself (direct annuloplasty) and those that tighten the mitral annulus via manipulation of the adjacent coronary sinus (indirect annuloplasty). Indirect annuloplasty devices include the Carillon Mitral Contour System (Cardiac Dimension) and the Monarc device (Edwards Lifesciences). The CE-marked Carillon Mitral Contour System is comprised of self-expanding proximal and distal anchors connected with a nitinol bridge, with the proximal end coronary sinus ostium and the distal anchor in the great cardiac vein. The size of the connection is controlled by a manual pull back on the catheter (CE-marked). The Carillon system was evaluated in the Carillon Mitral Annuloplasty Device European Union Study and the follow-up Tighten the Annulus Now study, with further studies planned.¹⁵ The Monarc system also involves 2 self-expanding stents connected by a nitinol bridge, with one end implanted in the coronary sinus via the internal jugular vein and the other in the great cardiac vein. Several weeks after implantation, the biologically degradable coating over the nitinol bridge degrades, allowing the bridge to shrink and the system to shorten. It has been evaluated in the Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation trial.¹⁶

Direct annuloplasty devices include the Mitralign Percutaneous Annuloplasty System (Mitralign) and the AccuCinch System (Guided Delivery Systems), both of which involve transcatheter placement of anchors in the MV; they are cinched or connected to narrow the mitral annulus. Other transcatheter direct annuloplasty devices under investigation include the enCorTC™ device (MiCardia), which involves a percutaneously insertable annuloplasty ring that is adjustable using radiofrequency energy, a variation on its CE-marked enCor_{sq} Mitral Valve Repair System, and the Cardioband Annuloplasty System (Valtech Cardio), an implantable annuloplasty band with a transfemoral venous delivery system.

Transcatheter Mitral Valve Replacement

Permavalve (Micro Interventional Devices), under investigation in the U.S., is a transcatheter MV replacement device that is delivered via the transapical approach. On June 5, 2017, the SAPIEN 3 Transcatheter Heart Valve (Edwards Lifesciences) was approved by the FDA as a MV replacement device. These replacement valves are outside the scope of this evidence review.

Medical Management

The standard treatment for patients with chronic secondary MR is medical management. Patients with chronic secondary MR should receive standard therapy for heart failure with reduced ejection fraction; standard management includes angiotensin-converting enzyme inhibitor (or angiotensin II receptor blocker or angiotensin receptor-neprilysin inhibitor), b-blocker and mineralocorticoid receptor antagonist, and diuretic therapy as needed to

treat volume overload.^{4.3} Resynchronization therapy may provide symptomatic relief, improve LV function, and in some patients, lessen the severity of MR.

Regulatory Status

In October 2013, the MitraClip Clip Delivery System (Abbott Vascular) was approved by the FDA through the premarket approval process for treatment of "significant symptomatic mitral regurgitation (MR $\geq 3+$) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at a prohibitive risk for mitral valve surgery by a heart team."¹⁷

FDA product code: NKM.

In March 2019, the FDA approved a new indication for MitraClip, for "treatment of patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation because of diminished left heart function (commonly known as secondary or functional mitral regurgitation) despite being treated with optimal medical therapy. Optimal medical therapy includes combinations of different heart failure medications along with, in certain patients, cardiac resynchronization therapy and implantation of cardioverter defibrillators."

RATIONALE

Summary of Evidence

For individuals who have symptomatic primary mitral regurgitation (MR) and at prohibitive risk for open surgery who receive transcatheter mitral valve repair (TMVR) using MitraClip, the evidence includes a single-arm prospective cohort with historical cohort and registry studies. Relevant outcomes are overall survival (OS), morbid events, functional outcomes, and treatment-related morbidity. The primary evidence includes the pivotal EVEREST II HRR and EVEREST II REALISM studies and Transcatheter Valve Therapy Registry studies. These studies have demonstrated that MitraClip implantation is feasible with a procedural success rate greater than 90%, 30-day mortality ranging from 2.3% to 6.4% (less than predicted Society of Thoracic Surgeons mortality risk score for MR repair or replacement; range, 9.5%-13.2%), post-implantation MR severity grade of 2+ or less in 82% to 93% of patients, and a clinically meaningful gain in quality of life (5- to 6-point gains in 36-Item Short-Form Health Survey scores). At 1 year, freedom from death and MR more than 2+ was achieved in 61% of patients but the 1-year mortality or heart failure hospitalization rates remain considerably high (38%). Conclusions related to the treatment effect on mortality based on historical controls cannot be made because the control groups did not provide unbiased or precise estimates of the natural history of patients eligible to receive MitraClip. Given that primary MR is a mechanical problem and there is no effective medical therapy, a randomized controlled trial (RCT) comparing MitraClip with medical management is not feasible or ethical. The post-marketing data from the U.S. is supportive that MitraClip surgery is being performed with short-term effectiveness and safety in a select patient population. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have heart failure and symptomatic secondary MR despite the use of maximally tolerated guideline-directed medical therapy who receive TMVR using MitraClip, the evidence includes a systematic review, 2 RCTs as well as multiple observational studies. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. The trials had discrepant results potentially related to differences in primary outcomes. The larger trial, with patients selected for nonresponse to maximally tolerated therapy, found a significant benefit for MitraClip after 2 years compared to medical therapy alone. Improvements in MR severity, quality of life measures, and functional capacity persisted to 36 months in patients who received TMVR. The systematic review confirmed the benefit of MitraClip found in the larger RCT, but had important methodological limitations. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic primary or SMR and are surgical candidates who receive TMVR using MitraClip, the evidence includes a systematic review, 1 RCT, and a retrospective comparative observational study in individuals aged ≥ 75 years. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. The RCT found that MitraClip did not reduce MR as often or as completely as the surgical control, although it could be safely implanted and was associated with fewer adverse events at 1 year. Long-term follow-up from the RCT showed that significantly more MitraClip patients required surgery for MV dysfunction than conventional surgery patients. For these reasons, this single trial is not definitive in demonstrating improved clinical outcomes with MitraClip compared with surgery. Additional RCTs are needed to corroborate these results. The observational study in individuals aged ≥ 75 years found that although MitraClip was associated with improved 1-year survival and a lower rate of all acute complications compared with surgical repair, it had lower 5-year survival and greater MR recurrence. The evidence is insufficient to determine s that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic primary or secondary MR who receive TMVR using devices other than MitraClip, the evidence includes primarily noncomparative feasibility studies. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. The body of evidence consists only of very small case series and case reports. Controlled studies, preferably RCTs, are needed to draw conclusions about the net health benefit. The evidence is insufficient to determine s that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Cardiology and American Heart Association

In 2020, the American College of Cardiology and American Heart Association released updated guidelines on the management of valvular heart disease.⁵ The guidelines state that TMVR is of benefit to patients with severely symptomatic primary MR who are at high or prohibitive risk for surgery, and to a subset of patients with secondary MR who remain severely symptomatic despite guideline-directed management and therapy for heart failure. Relevant recommendations on interventions for primary and secondary MR are shown in Table 1.

Table 1. Recommendations on Interventions for Primary and Secondary Mitral Regurgitation

Recommendation	COR	LOE
Primary MR		
In symptomatic patients with severe primary MR (Stage D), mitral valve intervention is recommended irrespective of LV systolic function	1 (Strong)	B-NR ¹
In asymptomatic patients with severe primary MR and LV systolic dysfunction (LVEF <60%, LVESD >40 mm) (Stage C2), mitral valve surgery is recommended	1 (Strong)	B-NR ¹
In patients with severe primary MR for whom surgery is indicated, mitral valve repair is recommended in preference to mitral valve replacement when the anatomic cause of MR is a degenerative disease, if a successful and durable repair is possible	1 (Strong)	B-NR ¹
In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF >60% and LVESD >40 mm) (Stage C1), mitral valve repair is reasonable when the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1% when it can be performed at a Primary or Comprehensive Valve Center	2a (Moderate)	B-NR ¹
In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF >60% and LVESD <40 mm) (Stage C1) but with a progressive increase in LV size or decrease in EF on >3 serial imaging studies, mitral valve surgery may be considered irrespective of the probability of a successful and durable repair	2b (Weak)	C-LD ²
In severely symptomatic patients (NYHA class III or IV) with primary severe MR and high or prohibitive surgical risk, TEER is reasonable if mitral valve anatomy is favorable for the repair procedure and patient life expectancy is at least 1 year	2a (Moderate)	B-NR ¹
In symptomatic patients with severe primary MR attributable to rheumatic valve disease, mitral valve repair may be considered at a Comprehensive Valve Center by an experienced team when surgical treatment is indicated, if a durable and successful repair is likely	2b (Weak)	B-NR ¹
In patients with severe primary MR where leaflet pathology is limited to less than one half the posterior leaflet, mitral valve replacement should not be performed unless mitral valve repair has been attempted at a Primary or Comprehensive Valve Center and was unsuccessful	3:Harm (Strong)	B-NR ¹
Secondary MR		
In patients with chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) who have persistent symptoms (NYHA class II, III, or IV) while on optimal GDMT for HF (Stage D), TEER is reasonable in patients with	2a (Moderate)	B-R ³

appropriate anatomy as defined on TEE and with LVEF between 20% and 50%, LVESD <70 mm, and pulmonary artery systolic pressure <70 mmHg		
In patients with severe secondary MR (Stages C and D), mitral valve surgery is reasonable when CABG is undertaken for the treatment of myocardial ischemia	2a (Moderate)	B-NR ¹
In patients with chronic severe secondary MR from atrial annular dilation with preserved LV systolic function (LVEF >50%) who have severe persistent symptoms (NYHA class III or IV) despite therapy for HF and therapy for associated AF or other comorbidities (Stage D), mitral valve surgery may be considered	2b (Weak)	B-NR ¹
In patients with chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) who have persistent severe symptoms (NYHA class III or IV) while on optimal GDMT for HF (Stage D), mitral valve surgery may be considered	2b (Weak)	B-NR ¹
In patients with CAD and chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) (Stage D) who are undergoing mitral valve surgery because of severe symptoms (NYHA class III or IV) that persist despite GDMT for HF, chordal-sparing mitral valve replacement may be reasonable to choose over downsized annuloplasty repair	2b (Weak)	B-R ³

Source: Adapted from Otto et al (2020)⁵.

¹Moderate, nonrandomized; ²Limited data; ³Moderate, randomized.

CABG: coronary artery bypass graft; CAD: coronary artery disease; COR: class of recommendation; GDMT: guideline-directed medical therapy; HF: heart failure; LOE: level of evidence; LV: left ventricular; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameters; MR: mitral regurgitation; MV: mitral valve; NYHA: New York Heart Association; TEE: transesophageal echocardiogram; TEER: transcatheter edge-to-edge repair

American College of Cardiology, American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons

The American College of Cardiology, American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons (2014) issued a position statement on transcatheter therapies for mitral regurgitation (MR).⁵⁶ This statement outlined critical components for successful transcatheter MR therapies and recommended ongoing research and inclusion of all patients treated with transcatheter MR therapies in a disease registry.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services (2015) issued a national coverage decision for the use of TMVR.⁵⁷

The Centers for Medicare & Medicaid Services determined that it would cover TMVR under Coverage with Evidence Development for the treatment of significant symptomatic MR when all of the following conditions are met:

"

1. The procedure is performed with a complete TMVR system that has received FDA [Food and Drug Administration] premarket approval (PMA) for that system's FDA-approved indication.
2. Both a cardiothoracic surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease have independently examined the patient face-to-face and evaluated the patient's suitability for mitral valve surgery and determination of prohibitive risk; and both surgeons have documented the rationale for their clinical judgment and the rationale is available to the heart team.
3. The patient (pre-operatively and post-operatively) is under the care of a heart team....

TMVR must be furnished in a hospital and with the appropriate infrastructure that includes but is not limited to:

- a. On-site active valvular heart disease surgical program with >2 hospital-based cardiothoracic surgeons experienced in valvular surgery;

- b. Cardiac catheterization lab or hybrid operating room/catheterization lab equipped with a fixed radiographic imaging system with flat-panel fluoroscopy, offering catheterization laboratory-quality imaging,
- c. Non-invasive imaging expertise including transthoracic/transesophageal/3D echocardiography, vascular studies, and cardiac CT studies; ...
- d. e. Post-procedure intensive care facility with personnel experienced in managing patients who have undergone open-heart valve procedures;
- f. Adequate outpatient clinical care facilities
- g. Appropriate volume requirements per the applicable qualifications below.

There are institutional and operator requirements for performing TMVR. The hospital must have the following:

- a. A surgical program that performs > 25 total mitral valve surgical procedures for severe MR per year of which at least 10 must be mitral valve repairs;
- b. An interventional cardiology program that performs > 1000 catheterizations per year, including > 400 percutaneous coronary interventions (PCIs) per year, with acceptable outcomes for conventional procedures compared to National Cardiovascular Data Registry (NCDR) benchmarks;
- c. The heart team must include:
 - 1. An interventional cardiologist(s) who:
 - performs > 50 structural procedures per year including atrial septal defects (ASD), patent foramen ovale (PFO) and trans-septal punctures; and,
 - must receive prior suitable training on the devices to be used; and,
 - must be board-certified in interventional cardiology or board-certified/eligible in pediatric cardiology or similar boards from outside the United States;
 - 2. Additional members of the heart team, including: cardiac echocardiographers, other cardiac imaging specialists, heart valve and heart failure specialists, electrophysiologists, cardiac anesthesiologists, intensivists, nurses, nurse practitioners, physician assistants, data/research coordinators, and a dedicated administrator;
- d. All cases must be submitted to a single national database;
- e. Ongoing continuing medical education (or the nursing/technologist equivalent) of 10 hours per year of relevant material;
- f. The cardiothoracic surgeon(s) must be board-certified in thoracic surgery or similar foreign equivalent.

- 4. The heart teams [sic] interventional cardiologist or a cardiothoracic surgeon must perform the TMVR. Interventional cardiologist(s) and cardiothoracic surgeon(s) may jointly participate in the intra-operative technical aspects of TMVR as appropriate.
- 5. The heart team and hospital are participating in a prospective, national, audited registry that: 1) consecutively enrolls TMVR patients; 2) accepts all manufactured devices; 3) follows the patient for at least one year; and, 4) complies with relevant regulations relating to protecting human research subjects....

The registry should collect all data necessary and have a written executable plan....

B. TMVR for MR uses that are not expressly listed as an FDA-approved indication when performed within a FDA-approved randomized clinical trial that fulfills all of the following:

- 1. TMVR must be performed by an interventional cardiologist or a cardiac surgeon. Interventional cardiologist(s) and cardiothoracic surgeon(s) may jointly participate in the intra-operative technical aspects of TMVR as appropriate.
- 2. As a fully-described, written part of its protocol, the clinical research study must critically evaluate the following questions at 12 months of longer follow-up:

What is the patient's post-TMVR quality of life (compared to pre-TMVR) at one year?

What is the patient's post-TMVR functional capacity (compared to pre-TMVR) at one year?"

In addition, the clinical research study must address a series of questions at one year post-procedure as outlined in the proposed decision memo.

REFERENCES

1. Chiam PT, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. *JACC Cardiovasc Interv.* Jan 2011; 4(1): 1-13. PMID 21251623
2. Fedak PW, McCarthy PM, Bonow RO. Evolving concepts and technologies in mitral valve repair. *Circulation.* Feb 19 2008; 117(7): 963-74. PMID 18285577
3. Carabello BA. The current therapy for mitral regurgitation. *J Am Coll Cardiol.* Jul 29 2008; 52(5): 319-26. PMID 18652937
4. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* Sep 23 2008; 52(13): e1-142. PMID 18848134
5. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* Feb 02 2021; 143(5): e72-e227. PMID 33332150
6. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. *J Am Coll Cardiol.* Jan 21 2014; 63(2): 185-6. PMID 24036029
7. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* Jul 11 2017; 70(2): 252-289. PMID 28315732
8. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J.* Oct 2012; 33(19): 2451-96. PMID 22922415
9. Diodato MD, Moon MR, Pasque MK, et al. Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. *Ann Thorac Surg.* Sep 2004; 78(3): 794-9; discussion 794-9. PMID 15336993
10. Wong DR, Agnihotri AK, Hung JW, et al. Long-term survival after surgical revascularization for moderate ischemic mitral regurgitation. *Ann Thorac Surg.* Aug 2005; 80(2): 570-7. PMID 16039207
11. Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. *J Am Coll Cardiol.* Jun 05 2007; 49(22): 2191-201. PMID 17543639
12. Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. *N Engl J Med.* Dec 04 2014; 371(23): 2178-88. PMID 25405390
13. Young A, Feldman T. Percutaneous mitral valve repair. *Curr Cardiol Rep.* Jan 2014; 16(1): 443. PMID 24281977
14. Minha S, Torguson R, Waksman R. Overview of the 2013 Food and Drug Administration Circulatory System Devices Panel meeting on the MitraClip Delivery System. *Circulation.* Aug 20 2013; 128(8): 864-8. PMID 23960257
15. Siminiak T, Wu JC, Haude M, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. *Eur J Heart Fail.* Aug 2012; 14(8): 931-8. PMID 22613584
16. Harnek J, Webb JG, Kuck KH, et al. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation). *JACC Cardiovasc Interv.* Jan 2011; 4(1): 115-22. PMID 21251638
17. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Mitral Valve Repair Device. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100009b.pdf. Accessed April 23, 2021.
18. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Percutaneous mitral valve repair. TEC Assessments 2014; Volume 29: Tab 4.
19. Reichenspurner H, Schillinger W, Baldus S, et al. Clinical outcomes through 12 months in patients with degenerative mitral regurgitation treated with the MitraClip(R) device in the ACCESS-Europe Phase I trial. *Eur J Cardiothorac Surg.* Oct 2013; 44(4): e280-8. PMID 23864216
20. Lim S, Kar S, Fail P, et al. The EVEREST II high surgical risk cohort: effectiveness of transcatheter reduction of significant mitral regurgitation in high surgical risk patients. *J Am Coll Cardiol.* 2013;61(10 Suppl):E1958.
21. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. *J Am Coll Cardiol.* Jul 15 2014; 64(2): 182-92. PMID 24184254
22. Ware J, Kosinski M, Bjorner JB, et al. User's Manual for the SF-36v2 Health Survey (2nd Ed). Lincoln, RI: QualityMetric; 2007.
23. Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. *J Am Coll Cardiol.* Mar 15 2016; 67(10): 1129-1140. PMID 26965532
24. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. *J Am Coll Cardiol.* Nov 07 2017; 70(19): 2315-2327. PMID 29096801
25. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. *J Am Coll Cardiol.* Jul 15 2014; 64(2): 172-81. PMID 25011722
26. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. *J Am Coll Cardiol.* Aug 18 2009; 54(8): 686-94. PMID 19679246
27. Chan PH, She HL, Alegria-Barrero E, et al. Real-world experience of MitraClip for treatment of severe mitral regurgitation. *Circ J.* 2012; 76(10): 2488-93. PMID 22785461

28. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. *J Am Coll Cardiol.* Jan 10 2012; 59(2): 130-9. PMID 22222076
29. Wan B, Rahnavardi M, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. *Ann Cardiothorac Surg.* Nov 2013; 2(6): 683-92. PMID 24349969
30. Bail DH, Doebler K. The MitraClip System: a systematic review of indications, procedural requirements, and guidelines. *Thorac Cardiovasc Surg.* Feb 2014; 62(1): 18-25. PMID 24297637
31. Estevez-Loureiro R, Franzen O, Winter R, et al. Echocardiographic and clinical outcomes of central versus noncentral percutaneous edge-to-edge repair of degenerative mitral regurgitation. *J Am Coll Cardiol.* Dec 24 2013; 62(25): 2370-2377. PMID 24013059
32. Grasso C, Ohno Y, Attizzani GF, et al. Percutaneous mitral valve repair with the MitraClip system for severe mitral regurgitation in patients with surgical mitral valve repair failure. *J Am Coll Cardiol.* Mar 04 2014; 63(8): 836-8. PMID 24161329
33. Munkholm-Larsen S, Wan B, Tian DH, et al. A systematic review on the safety and efficacy of percutaneous edge-to-edge mitral valve repair with the MitraClip system for high surgical risk candidates. *Heart.* Mar 2014; 100(6): 473-8. PMID 23813844
34. Swaans MJ, Bakker AL, Alipour A, et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. *JACC Cardiovasc Interv.* Aug 2014; 7(8): 875-81. PMID 25147032
35. Philip F, Athappan G, Tuzcu EM, et al. MitraClip for severe symptomatic mitral regurgitation in patients at high surgical risk: a comprehensive systematic review. *Catheter Cardiovasc Interv.* Oct 01 2014; 84(4): 581-90. PMID 24905665
36. Vakil K, Roukoz H, Sarraf M, et al. Safety and efficacy of the MitraClip(R) system for severe mitral regurgitation: a systematic review. *Catheter Cardiovasc Interv.* Jul 01 2014; 84(1): 129-36. PMID 24323764
37. Bail DH. (Meta)-analysis of safety and efficacy following edge-to-edge mitral valve repair using the MitraClip system. *J Interv Cardiol.* Feb 2015; 28(1): 69-75. PMID 25689550
38. Velazquez EJ, Samad Z, Al-Khalidi HR, et al. The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. *Am Heart J.* Nov 2015; 170(5): 1050-1059.e3. PMID 26542516
39. Hayashida K, Yasuda S, Matsumoto T, et al. AVJ-514 Trial - Baseline Characteristics and 30-Day Outcomes Following MitraClip (R) Treatment in a Japanese Cohort. *Circ J.* Jul 25 2017; 81(8): 1116-1122. PMID 28321004
40. Kumar A, Al-Khafaji J, Shariff M, et al. Percutaneous mitral valve repair for secondary mitral valve regurgitation: A systematic review and meta-analysis. *Eur J Intern Med.* Aug 2020; 78: 107-112. PMID 32094019
41. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N Engl J Med.* Dec 13 2018; 379(24): 2297-2306. PMID 30145927
42. Atianzar K, Zhang M, Newhart Z, et al. Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip. *Interv Cardiol.* Feb 2019; 14(1): 45-47. PMID 30858892
43. lung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. *Eur J Heart Fail.* Dec 2019; 21(12): 1619-1627. PMID 31476260
44. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N Engl J Med.* Dec 13 2018; 379(24): 2307-2318. PMID 30280640
45. Mack MJ, Lindenfeld J, Abraham WT, et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. *J Am Coll Cardiol.* Mar 02 2021; 77(8): 1029-1040. PMID 33632476
46. Nishimura RA, Bonow RO. Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials. *N Engl J Med.* Dec 13 2018; 379(24): 2374-2376. PMID 30575469
47. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail.* Aug 2017; 23(8): 628-651. PMID 28461259
48. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J.* Sep 21 2017; 38(36): 2739-2791. PMID 28886619
49. Takagi H, Ando T, Umemoto T. A review of comparative studies of MitraClip versus surgical repair for mitral regurgitation. *Int J Cardiol.* Feb 01 2017; 228: 289-294. PMID 27865200
50. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med.* Apr 14 2011; 364(15): 1395-406. PMID 21463154
51. Mauri L, Garg P, Massaro JM, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. *Am Heart J.* Jul 2010; 160(1): 23-9. PMID 20598968
52. Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. *J Am Coll Cardiol.* Jul 23 2013; 62(4): 317-28. PMID 23665364
53. Feldman T, Kar S, Elmariah S, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. *J Am Coll Cardiol.* Dec 29 2015; 66(25): 2844-2854. PMID 26718672
54. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. *J Thorac Cardiovasc Surg.* Jul 2019; 158(1): 86-94.e1. PMID 30797588
55. Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. *Circulation.* Jul 28 2009; 120(4): 326-33. PMID 19597051
56. O'Gara PT, Calhoun JH, Moon MR, et al. Transcatheter therapies for mitral regurgitation: a professional society overview from the American College of Cardiology, The American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions Foundation, and The Society of Thoracic Surgeons. *J Thorac Cardiovasc Surg.* Mar 2014; 147(3): 837-49. PMID 24529172
57. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Transcatheter MITRAL Valve Repair (TMVR) (20.33). 2015; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx>

NCDId=363&ncdver=1&CoverageSelection=National&Keyword=mitral&KeywordLookUp=Title&KeywordSearchType=And&bc=gAAAABAAAAAAAAA%3d%3d&. Accessed April 23, 2021.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2015	New policy	Transcatheter mitral valve repair considered medically necessary for degenerative mitral regurgitation in patients at prohibitive surgical risk.
September 2016	Replace policy	Policy updated with literature review through March 30, 2016; references 25, 29, 31, 37, and 41 added. Policy statements unchanged.
September 2018	Replace policy	Policy updated with literature review through March 5, 2018; references 27-29, 34-36, and 53 added. "Cleared" changed to "approved" in the medically necessary policy statement. In the policy degenerative mitral regurgitation was replaced with primary mitral regurgitation and functional mitral regurgitation was replaced with secondary mitral regurgitation including the policy statement to be in consistent with language used in the guidelines. Data from FDA documents were added.
September 2019	Replace policy	Policy updated with literature review through March 6, 2019, references 50-51 added. Regulatory status section updated with new indication. Policy statement added; transcatheter mitral valve repair with an FDA-approved device considered medically necessary for patients with heart failure and secondary mitral regurgitation despite the use of maximally tolerated guideline-directed medical therapy. Information regarding optimal medical therapy added to the Policy Guidelines section.
September 2020	Replace policy	Policy updated with literature review through March 23, 2020; references added. Policy statements unchanged.
September 2021	Replace policy	Policy updated with literature review through March 30, 2021; references added; guidelines section updated. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.